CART secreted cytokine blockers successfully antagonized the actions of IL6 and IL1 by releasing large amounts of anti-IL6 scFv and IL1RA, and all patients showed complete response, only one patient developed grade 2 CRS and none developed any neurotoxicity symptoms. Here, IL6 is linked to congenital rubella syndrome.